New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
06:37 EDTALXNAlexion granted ODD to Soliris by FDA
Alexion Pharmaceuticals announced that the FDA has granted an orphan drug designation, or ODD, to Soliris, a first-in-class terminal complement inhibitor, for the prevention of delayed graft function, or DGF in renal transplant patients. DGF is an early and serious complication of organ transplantation that is characterized by the failure of a transplanted organ to function normally immediately following transplantation.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
08:26 EDTALXNAlexion coverage assumed with an Outperform at Oppenheimer
Subscribe for More Information
April 24, 2015
08:33 EDTALXNAlexion has reached attractive entry point, says SunTrust
Subscribe for More Information
April 23, 2015
11:23 EDTALXNAlexion weakness a buying opportunity, says Cowen
06:41 EDTALXNAlexion backs FY15 non-GAAP EPS view $5.60-$5.80, consensus $5.87
Subscribe for More Information
06:39 EDTALXNAlexion reports Q1 non-GAAP EPS $1.28, consensus $1.33
Reports Q1 revenue $600.3M, consensus $591.38M. Reports Q1 net product sales of Soliris $600.3M vs. $566.6M a year ago.
April 22, 2015
15:50 EDTALXNNotable companies reporting before tomorrow's open
Subscribe for More Information
April 20, 2015
07:18 EDTALXNAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use